Nanologica AB (publ) (”Nanologica” or ”the Company”) publishes an information document regarding the directed share issues of approximately SEK 13.7 million in total and rights issue of approximately SEK 82.5 million, before issue costs, which was resolved by the board of directors on 30 January 2026 and subsequently approved by the extraordinary general meeting held on 4 March 2026 (“The Issues”). The information document has been registered with the Swedish Financial Supervisory Authority and is available on the Company’s website.
Information document
In connection with the Issues, the Company has prepared an information document (the “Information Document“) in accordance with Article 1.4 db and 1.5 ba of Regulation (EU) 2017/1129 of the European Parliament and of the Council (EU) 2017/1129 of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended (the “Prospectus Regulation“). The Information Document has been prepared in accordance with the requirements of Annex IX to the Prospectus Regulation.
Nanologica announces today that the Information Document has been registered with the Swedish Financial Supervisory Authority and is available on the Company’s website www.nanologica.com, and on Bergs Securities AB:s website, www.bergssecurities.se. Application forms for subscription without preferential rights will be available on Bergs Securities AB’s website.
Timetable for the rights issue
| 6 March 2026 | First day of trading in the Company’s share including the right to subscribe for shares with the support of supscription rights |
| 9 March 2026 | Record date for the right to participate in the Rights Issue |
| 11 March – 25 March 2026 | Subscription period in the Rights Issue |
| 11 March – 20 March 2026 | Trading in subscription rights |
| 11 March – 10 April 2026 | Trading with BTA |
| Around 26 March 2026 | Announcement of the outcome of the rights issue |
Advisors
Nanologica has engaged Redeye AB and Navia Corporate Finance AB as Joint Bookrunners and Bergs Securities AB as Joint Bookrunner and issuing agent, as well as Advokatfirman Lindahl KB as legal advisor in connection with the Rights Issue.